DeFi Development Corp. to Host Twitter Spaces Explaining ELOCs, S-1s, and Capital Strategy
Globenewswire· 2025-06-12 17:00
BOCA RATON, FL, June 12, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first U.S. public company with a treasury strategy built to accumulate and compound Solana (“SOL”), announced today it will host a live Twitter Spaces event on Monday, June 16, 2025 at 1:00 PM ET to walk investors through the company’s recent S-1 filings, its newly announced $5 billion Equity Line of Credit (ELOC), and broader public market capital strategy. The session will featu ...
Giant-Cell Arteritis Market Heats up with AbbVie's RINVOQ Approval | DelveInsight
GlobeNewswire News Room· 2025-06-12 17:00
Core Insights - AbbVie's RINVOQ (upadacitinib) has received FDA approval for the treatment of giant cell arteritis, marking it as the first oral JAK inhibitor approved for this condition in Western countries, and the ninth indication for the drug [1][6] Group 1: Market Dynamics - The approval of RINVOQ has intensified competition among pharmaceutical companies in the giant cell arteritis market [1] - DelveInsight estimates the giant cell arteritis market size to grow from USD 960 million in 2023 at a significant CAGR by 2034, driven by factors such as an increasing geriatric population and rising prevalence of cardiovascular disorders [14] Group 2: Treatment Landscape - The primary treatment for giant cell arteritis has traditionally involved high doses of corticosteroids like prednisone, with the aim of preventing serious complications such as blindness [3] - ACTEMRA/ROACTEMRA (tocilizumab) was the first approved treatment for giant cell arteritis in Europe, with its approval supported by the Phase III GiACTA study demonstrating improved remission rates [4][7] - RINVOQ's pivotal Phase 3 SELECT-GCA trial showed that 46.4% of patients achieved sustained remission with RINVOQ compared to 29.0% on placebo [7] Group 3: Emerging Therapies - Companies like Novartis and CSL/Kiniksa Pharmaceuticals are conducting clinical trials for new treatment options, indicating a need for more effective therapies in the giant cell arteritis space [10][12] - The anticipated launch of emerging therapies is expected to transform the market landscape, offering new standards of care and opportunities for innovation [13]
Leidos Welcomes Nearly 900 Summer Interns from 290 Colleges and Universities
Prnewswire· 2025-06-12 17:00
RESTON, Va., June 12, 2025 /PRNewswire/ -- Every day, Leidos (NYSE: LDOS) employees tackle customers' most vexing challenges in defense, homeland security, information technology, intelligence, health, energy, and more. This summer in the U.S., nearly 900 summer interns from 290 colleges and universities are gaining valuable experience working across all aspects of the technology company's operations.Leidos has more than tripled its summer intern class size since 2016, reflecting a focus on attracting, deve ...
Zimbabwe's export ban could reshape global lithium supply chain
Proactiveinvestors NA· 2025-06-12 16:57
About this content About Sam Kiri Sam has over 10 years of capital markets and asset management experience in both North America and the Pacific Rim, with primary focus on Resources and Oil & Gas sectors. He spent three years with Scotia Bank as an International Equity analyst, and was responsible for the management of the Scotia Pacific Rim Mutual Fund. Sam is a CFA Charter Holder, a qualified Management Accountant and has a MBA in Finance. Sam was involved in several public listings in London and Toro ...
Chime opens at $43 in Nasdaq debut after pricing IPO above expected range
CNBC· 2025-06-12 16:56
CEO of Chime, Chris Britt, center right, rings the opening bell during the company's initial public offering at the Nasdaq MarketSite on June 12, 2025 in New York City.Chime opened at $43 in its Nasdaq debut on Thursday after selling shares at $27 each in an IPO that valued the online banking company at $11.6 billion.Late Wednesday, Chime raised about $700 million in its offering, and existing investors sold an additional $165 million worth of shares. The stock is trading under the ticker symbol CHYM.Chime' ...
How CYBR is Leveraging AI to Cement Its Identity Security Leadership
ZACKS· 2025-06-12 16:56
Key Takeaways CYBR is integrating Secure AI Agents and CORA AI to enhance its identity security platform. The platform secures human, machine, and AI identities against evolving cybersecurity threats. CYBR's subscription ARR rose 65% YoY in Q1 2025, with 2025 revenue expected at up to $1.323 billion.CyberArk (CYBR) is rapidly enhancing the capabilities of its identity security platform with AI integration. CyberArk Secure AI Agents Solution and CORA AI are two recent additions to its portfolio. CYBR is al ...
Talen: Up Almost 400%, What's Built Into Today's Stock Price?
Seeking Alpha· 2025-06-12 16:54
Rob Howard is Co-Manager at Boiling Point Resources. Rob has extensive background in the utility industry working at Baltimore Gas and Electric for over seven years. While there he spent time in Distribution Engineering, Demand Side Management, and Rates and Regulation. This hands on experience has given him a deep understanding of industry issues. After his industry experience Rob moved to the investments business, where he has been following utilities since 2002. Rob has a BS in Engineering and a BA in Ec ...
Affirm's Active Merchants Rise: A Strategic Advantage in BNPL Space?
ZACKS· 2025-06-12 16:51
Key Takeaways AFRM grew active merchants 23% YoY in fiscal 3Q 2025, reaching around 358,000 partners. GMV surged 36% YoY to $8.6B in fiscal 3Q 2025, with FY25 GMV forecasted at $35.7-$36B. Merchant network revenues rose 34.3% YoY, backed by key partnerships and product enhancements.Affirm Holdings, Inc. (AFRM) is primarily focusing on growth and merchant expansion. It is strengthening its position in the competitive market of Buy Now Pay Later (BNPL) through merchant adoptions on its platform. The company ...
Pixel Gets New Features and Android 16: Should You Hold GOOGL Stock?
ZACKS· 2025-06-12 16:51
Key Takeaways GOOGL adds AI tools to Pixel, Photos, Search, and Cloud, boosting device shipments and user engagement. Alphabet shares rose 11.2% in a month, outpacing Apple, Microsoft, and Amazon amid AI-fueled momentum. AI Overview, Circle to Search, and NVIDIA GPU deals are driving growth in Search and Google Cloud.Alphabet (GOOGL) is adding new features to Pixel, including the new VIPs widget, stickers on Gboard with Pixel Studio (using Generative AI), improved photography skills, AI-powered editing in ...
Why Now is the Time to Buy PONY Stock Post a 29.5% Drop in a Month
ZACKS· 2025-06-12 16:51
Key Takeaways PONY shares fell 29.5% in 30 days after surging more than 245% from mid-April to mid-May 2025. The company plans to grow its robotaxi fleet to over 1,000 vehicles by the end of 2025. PONY's local sourcing and key partnerships help shield it from tariff risks and supply shocks.Pony AI (PONY) , an autonomous-driving company based in Guangzhou, China, has seen its shares tumble 29.5% over the past 30 days, faring worse than the Zacks Transportation - Equipment and Leasing industry’s 1.4% decli ...